CLINICAL TRIAL
COMPARATIVE STUDY
JOURNAL ARTICLE
MULTICENTER STUDY
Add like
Add dislike
Add to saved papers

A prospective, multi-centered study of the treatment of idiopathic sudden sensorineural hearing loss with combination therapy versus high-dose prednisone alone: a 139 patient follow-up.

OBJECTIVE: To compare combination therapy (high-dose prednisone taper (HDPT) + intratympanic dexamethasone (IT-Dex)) hearing recovery results in ISSNHL patients with those treated with HDPT alone.

DESIGN: Prospective, multicentered trial.

SETTING: Tertiary referral center.

PATIENTS: Eighty ISSNHL patients with class C or D hearing.

INTERVENTION: Eighty qualifying patients were treated with IT-Dex (10 mg/ml) every week for 3 weeks concomitant with HDPT (60 mg/d for 7 d with 7-d taper) and followed prospectively.

MAIN OUTCOME MEASURE(S): Four-tone pure tone average (PTA) at 0.25, 0.5, 1, and 2 kHz and speech discrimination scores (SDS) 2 months posttreatment; Hearing results compared retrospectively with those of 59 ISSNHL treated with HDPT alone.

RESULTS: Combination therapy and HDPT alone both provided a statistically significant benefit in audiometric parameters, especially if treated within 7 days of onset. However, 49% versus 29% (p = 0.02) of class D patients receiving combination therapy versus HDPT achieved serviceable hearing. Patients receiving combination therapy versus HDPT experienced a significantly greater improvement in PTA (34.1 ± 27 dB versus 12.0 ± 21 dB; p < 0.0001) and SDS (49.9.2 ± 38% versus 19.2 ± 36%; p < 0.0001) while achieving a significantly better final PTA (50.6 ± 28 dB versus 65.5 ± 29 dB; p = 0.005) and SDS (62.4 ± 40% versus 44.7 ± 41%; p = 0.01). Approximately 56% of class D and 40% of profound patients treated within 7 days with combination therapy achieved serviceable hearing.

CONCLUSION: Combination therapy offers ISSNHL patients the highest likelihood of achieving class A and B hearing. Differential results with combination therapy and HDPT compared with previous studies suggest time- and dose-dependent responses to the treatment of ISSNHL.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app